Abstract
Background Tildrakizumab (TIL), a high affinity, humanised, IgG1/κ monoclonal antibody for IL-23p19, recently demonstrated efficacy in patients with chronic plaque psoriasis in two, phase 3 clinical trials. Objectives To examine...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have